Loading...
Loading...
Spectrum Pharmaceuticals, Inc.
SPPI, a biotechnology company with
fully integrated commercial and drug development operations with a primary
focus in oncology and hematology, today provided an update regarding
anticipated milestones for the analysis of data and potential regulatory
filing related to the pivotal, registrational BELIEF trial of belinostat, a
novel histone deacetylase (HDAC) inhibitor. On September 21, 2012, Topotarget
A/S, Spectrum's collaboration partner for the joint development of belinostat,
reported preliminary clinical results for the BELIEF trial, which is
evaluating the efficacy and safety of belinostat for the treatment of patients
with relapsed/refractory peripheral T-cell lymphoma (PTCL). Spectrum is
continuing to collect and analyze the data from the trial, and database lock
is expected to occur in November/December 2012, following which a definitive
determination of the primary endpoint of overall response rate (ORR) will be
calculated.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in